journal
MENU ▼
Read by QxMD icon Read
search

Expert Opinion on Pharmacotherapy

journal
https://www.readbyqxmd.com/read/29224373/pharmacotherapy-and-treatment-options-for-hiv-associated-nephropathy
#1
Steven Menez, Mohamad Hanouneh, Blaithin A McMahon, Derek M Fine, Mohamed G Atta
Human immunodeficiency virus (HIV) remains a worldwide disease with significant mortality and morbidity. There are a multitude of HIV-related kidney diseases including HIV-associated nephropathy (HIVAN) most prominently. The risk of developing HIVAN increases with decreasing CD4 count, higher viral load, and based on genetic factors. The mortality rate for those with HIVAN-end stage renal disease (ESRD) remains 2.5-3 times higher than ESRD patient without HIVAN. Areas Covered: The epidemiology of HIVAN, particularly risk assessment will be explored in this review...
December 9, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29219629/pharmacotherapy-options-for-managing-chemotherapy-induced-peripheral-neurotoxicity
#2
Guido Cavaletti, Paola Marmiroli
Prevention and treatment of chemotherapy-induced peripheral neurotoxicity (CIPN) are clinically-relevant unmet needs. Despite extensive efforts at the preclinical and clinical levels, no effective pharmacological interventions are available, and this unsatisfactory situation reflects a combination of methodological issues and a lack of effectiveness of the tested drugs. Areas covered: This non-systematic, but unbiased review is based on published papers available in PubMed and screened using the broad search string [chemotherapy (and) neuropathy (and) treatment] to analyze the reported data...
December 8, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29212386/efficacy-and-safety-of-sotagliflozin-in-treating-diabetes-type-1
#3
Marc S Rendell
INTRODUCTION: Sotagliflozin is the first dual SGLT1/SGLT2 inhibitor developed for use in diabetes. Sotagliflozin blocks SGLT2 in the kidneys and SGLT1 in the intestines resulting in reduced early phase glucose absorption and increased blood levels of GLP-1 and PYY. Urinary glucose excretion is lower than with other agents as a result of decreased glucose absorption. The primary development effort to date has been in Type 1 diabetes. AREAS COVERED: The published information on sotagliflozin is reviewed, along with the recent results of several pivotal Type 1 diabetes trials...
December 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29212383/menstrual-migraine-a-review-of-current-and-developing-pharmacotherapies-for-women
#4
G Allais, Giulia Chiarle, Silvia Sinigaglia, Chiara Benedetto
Migraine is one of the most common neurological disorders in the general population. It affects 18% of women and 6% of men. In more than 50% of women migraineurs the occurrence of migraine attacks correlates strongly with the perimenstrual period. Menstrual migraine is highly debilitating, less responsive to therapy, and attacks are longer than those not correlated with menses. Menstrual migraine requires accurate evaluation and targeted therapy, that we aim to recommend in this review. Areas covered: This review of the literature provides an overview of currently available pharmacological therapies (especially with triptans, anti-inflammatory drugs, hormonal strategies) and drugs in development (in particular those acting on calcitonin gene-related peptide) for the treatment of acute migraine attacks and the prophylaxis of menstrual migraine...
December 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29212381/lowering-side-effects-of-nsaid-usage-in-osteoarthritis-recent-attempts-at-minimizing-dosage
#5
Kevin H Maniar, Ian A Jones, C Thomas Vangsness, Rayudu Gopalakrishna
Introduction Osteoarthritis is a burdensome disease that causes progressive damage to articular cartilage. Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the preferred treatments for symptomatic relief. However, NSAIDs can cause serious dose-dependent side effects, which has prompted experts to recommend the minimization of NSAID dosage. Areas Covered This review focuses on three broad strategies that are currently being investigated or implemented to minimize NSAID dosage: nano-formulation, encapsulation, and topical delivery...
December 7, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29202593/ipragliflozin-and-sodium-glucose-transporter-2-inhibitors-to-reduce-liver-fat-will-the-prize-we-sought-be-won
#6
Kalliopi Pafili, Efstratios Maltezos, Nikolaos Papanas
No abstract text is available yet for this article.
December 5, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29195487/efficacy-of-levomilnacipran-extended-release-in-treating-major-depressive-disorder
#7
Renee-Marie Ragguett, Samantha J Yim, Peter T Ho, Roger S McIntyre
Major depressive disorder (MDD) is the leading cause of disability worldwide with a heterogeneous symptom profile. Levomilnacipran extended release (ER) (Fetzima), a SNRI, has been approved by the Food and Drug Administration for treatment of MDD. While categorized as a SNRI, in contradistinction to other approved SNRIs, levomilnacipran exhibits differential affinity for the norepinephrine reuptake transporter when compared to the serotonin reuptake transporter. Areas covered: Completed clinical trials which focused on levomilnacipran ER administered in those with MDD were included in this drug evaluation...
December 1, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29185822/safety-and-efficacy-of-ipragliflozin-in-japanese-patients-with-type-2-diabetes-in-real-world-clinical-practice-interim-results-of-the-stella-long-term-post-marketing-surveillance-study
#8
Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi, Satoshi Uno
BACKGROUND: Data regarding the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the real-world setting in Japan are limited. The STELLA-LONG TERM study is an ongoing 3-year post-marketing surveillance study of ipragliflozin in type 2 diabetes (T2D) patients. Here, we report the interim results (including 3-, 12-, and 24-month data). RESEARCH DESIGN AND METHODS: All Japanese patients with T2D who were first prescribed ipragliflozin between July 17, 2014, and October 15, 2015, at participating centers in Japan were registered in STELLA-LONG TERM...
November 29, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29183228/recommendations-for-buprenorphine-and-methadone-therapy-in-opioid-use-disorder-a-european-consensus
#9
Maurice Dematteis, Marc Auriacombe, Oscar D'Agnone, Lorenzo Somaini, Néstor Szerman, Richard Littlewood, Farrukh Alam, Hannu Alho, Amine Benyamina, Julio Bobes, Jean Pierre Daulouede, Claudio Leonardi, Icro Maremmani, Marta Torrens, Stephan Walcher, Michael Soyka
Management of patients with opioid use disorder (OUD) commonly includes opioid agonist therapy (OAT) as a part of an integrated treatment plan. These interventions are associated with proven benefits to the individual and society. Areas covered: The use of methadone and buprenorphine within an integrated treatment plan in the management of patients with OUD: this work provides consensus recommendation on pharmacotherapy in OUD to assist clinicians with practical decision making in this field. Expert opinion: Pharmacotherapy is recommended as part of an integrated OUD treatment approach with psychosocial interventions, with the goal of reducing risks of illicit opioid use, overdose mortality, infection with HIV or HCV, improving health, psychological and social outcomes...
November 29, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29172855/lenalidomide-in-combination-or-alone-as-maintenance-therapy-following-autologous-stem-cell-transplant-in-patients-with-multiple-myeloma-a-review-of-options-for-and-against
#10
Paul G Richardson, Sarah A Holstein, Robert L Schlossman, Kenneth C Anderson, Michel Attal, Philip L McCarthy
Lenalidomide has multifaceted antimyeloma properties, including direct tumoricidal and immunomodulatory effects. Several randomized controlled trials have demonstrated improved patient outcomes with lenalidomide maintenance after autologous stem cell transplant (ASCT) in patients with newly diagnosed multiple myeloma (NDMM). Currently, single-agent lenalidomide is the only approved post-ASCT maintenance therapy in the United States and European Union for patients with NDMM. Areas covered: This review article summarizes the efficacy and safety data of lenalidomide maintenance, as monotherapy and in combination with other agents, following ASCT in patients with NDMM...
November 27, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29172834/managing-and-maintaining-bone-mineral-density-in-diabetes-patients-with-pharmacotherapy
#11
C Y Fixen, Danielle R Fixen
The population of patients with osteoporosis and diabetes is increasing as the aging population increases. Loss of bone mineral density occurs in patients with diabetes but is not always a priority in the practice setting. The aim of this review is to discuss clinical considerations when managing osteoporosis in patients with diabetes. Areas covered: The pathophysiology of decreased bone mineral density in patients with diabetes is discussed. Additionally, diabetic risk factors for fracture, such as hypoglycemia, the National Osteoporosis Foundation recommendations for osteoporosis, and secondary causes of osteoporosis, including disease and medication related causes, are discussed...
November 27, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29172818/new-pharmacotherapy-for-the-treatment-of-glaucoma
#12
Emily M Schehlein, Gary Novack, Alan L Robin
Glaucoma is the second leading cause of blindness in the world and current pharmacotherapies for glaucoma have remained relatively unchanged (with the exception of fixed combinations of previously available medications) since the mid-1990s with the development of prostaglandin analogues. Now, with both new formulations and new classes of medications with novel mechanisms of action, the medical therapy of glaucoma may be heralding a new dawn in medical management. Areas covered: This review outlines new topical therapies for intraocular pressure (IOP) lowering treatment, in addition to new formulations, preservative-free options, and advances in glaucoma medical therapy delivery...
November 26, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29171774/advances-in-treating-psoriasis-in-the-elderly-with-small-molecule-inhibitors
#13
Abigail Cline, Leah A Cardwell, Steven R Feldman
Due to the chronic nature of psoriasis, the population of elderly psoriasis patients is increasing. However, many elderly psoriatic patients are not adequately treated because management is challenging as a result of comorbidities, polypharmacy, and progressive impairment of organ systems. Physicians may hesitate to use systemic or biologic agents in elderly psoriasis patients because of an increased risk of adverse events in this patient population. Small molecule medications are emerging as promising options for elderly patients with psoriasis and other inflammatory conditions...
November 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29171767/can-intercalating-chemotherapy-with-epidermal-growth-factor-receptor-inhibitors-delay-development-of-treatment-resistance-in-advanced-non-small-cell-lung-cancer
#14
Anna La Salvia, Emmanuele De Luca, Antonio Rossi, Massimo Di Maio
No abstract text is available yet for this article.
November 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29171761/new-agents-for-the-management-of-resistant-metastatic-breast-cancer
#15
Jesus Anampa, Joseph A Sparano
Metastatic breast cancer (MBC) is an incurable disease and treatment is directed towards symptom palliation and survival prolongation. Treatment selection in patients is based on tumor biology, age, comorbidities, performance status, tumor burden, and prior treatment history. Areas covered: This present review summarizes the recent treatment strategies in the management of MBC, highlighting regimens after first-line therapy. Topics discussed include new strategies for endocrine therapy, anti-HER2 therapy, and promising strategies for the management of triple negative breast cancer...
November 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29169282/efficacy-of-buparlisib-in-treating-breast-cancer
#16
Marie Robert, Jean-Sébastien Frenel, Emmanuelle Bourbouloux, Dominique Berton Rigaud, Anne Patsouris, Paule Augereau, Carole Gourmelon, Mario Campone
Breast cancer is the most frequent cancer in women. Despite a decline in breast cancer mortality, prognosis of advanced breast cancer remains poor. In a desperate need to improve breast cancer outcomes, newer agents that target molecular pathways are being tested. Deregulation of the phosphoinositide 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) is frequently found in breast cancer. This can lead to resistance of endocrine therapy and anti-HER2 therapies. Targeting this pathway may restore sensitivity to these compounds...
November 24, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29141463/once-monthly-injection-of-paliperidone-palmitate-in-patients-with-recently-diagnosed-and-chronic-schizophrenia-a-post-hoc-comparison-of-efficacy-and-safety
#17
Tianmei Si, Jianmin Zhuo, Ibrahim Turkoz, Maju Mathews, Wilson Tan, Yu Feng
BACKGROUND: The use of long-acting injectable antipsychotics in recently diagnosed schizophrenia remains less explored. We evaluated the efficacy and safety of paliperidone palmitate once-monthly (PP1M) treatment in adult patients with recently diagnosed vs. chronic schizophrenia. RESEARCH DESIGN AND METHODS: These post-hoc analyses included two multicenter studies. Study 1 (NCT01527305) enrolled recently diagnosed (≤5 years) and chronic (>5 years) patients; Study 2 (NCT01051531) enrolled recently diagnosed patients only...
November 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29141460/safety-and-efficacy-of-metformin-up-titration-in-japanese-patients-with-type-2-diabetes-mellitus-treated-with-vildagliptin-and-low-dose-metformin
#18
Luka Suzuki, Akio Kanazawa, Hirotsugu Uzawa, Yusuke Osonoi, Atushi Masuyama, Kosuke Azuma, Kageumi Takeno, Naoko Takayanagi, Junko Sato, Yuki Someya, Koji Komiya, Hiromasa Goto, Tomoya Mita, Fuki Ikeda, Takeshi Ogihara, Tomoaki Shimizu, Chie Ohmura, Miyoko Saito, Takeshi Osonoi, Hirotaka Watada
BACKGROUND: This study investigated the safety and efficacy of metformin up-titration in Japanese patients with type 2 diabetes mellitus treated with vildagliptin (100 mg/day) and low-dose metformin (500 or 750 mg/day). RESEARCH DESIGN AND METHODS: Fifty patients were randomly allocated to the control group (maintaining the initial low-dose of metformin) and the dose increase group (up-titrating of metformin to 1,500-2,250 mg/day) for 24 weeks. The primary outcome was change in HbA1c from baseline to 24 weeks...
November 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29140112/a-2017-review-of-pharmacotherapy-for-treating-focal-epilepsy-where-are-we-now-and-how-will-treatment-develop
#19
Andreas Schulze-Bonhage
Focal epilepsy is the most common type of epilepsy with approximately 30 million patients affected worldwide. There is a major challenge to develop new antiepileptic treatments as currently approximately one third of patients remain uncontrolled under our best standards of care. Areas covered: An overview is given on first- and second generation antiepileptic drugs and their mechanisms of action, and on recent new strategies for antiepileptic targets, including drugs aiming at disease modification. Expert opinion: Newer antiepileptic drugs have enabled a better tolerated and individualized treatment for many patients...
November 15, 2017: Expert Opinion on Pharmacotherapy
https://www.readbyqxmd.com/read/29115881/a-review-of-current-and-developing-fixed-dose-laba-lama-combinations-for-treating-copd
#20
Chitra Lal, Charlie Strange
The current GOLD (Global Initiative for Chronic Obstructive Lung Disease) recommendations suggest using long acting β2 agonists (LABA) and long acting muscarinic antagonists (LAMA) in combination for group B COPD patients with persistent symptoms, group C COPD patients with further exacerbations on LAMA therapy alone and for group D COPD patients with or without combination with inhaled corticosteroids (ICS). Thus, there is a lot of interest in developing LABA/LAMA combinations for maintenance therapy of chronic stable COPD...
November 15, 2017: Expert Opinion on Pharmacotherapy
journal
journal
34813
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"